Dry Age-related Macular Degeneration Pipeline Analysis: 40+ Companies are working to improve the Treatment Space

DelveInsight's, "Dry Age-Related Macular Degeneration Pipeline Insight, 2022," report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in the Dry Age-Related Macular Degeneration pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key takeaways from the Dry Age-related Macular Degeneration Pipeline Report
• DelveInsight's Dry Age-related Macular Degeneration Pipeline analysis depicts a robust space with 45+ active players working to develop 45+ pipeline therapies.
• Some of the key pharmaceutical players working to develop potential drug candidates to improve the Dry Age-related Macular Degeneration treatment landscape include Alkeus Pharmaceuticals, Dobecure, Iveric Bio, Mitotech, Stealth BioTherapeutics, Allergo Ophthalmics, Gyroscope Therapeutics, Gemini Therapeutics, Luxa Biotechnology, CHABiotech CO., Ltd, Regenerative Patch Technologies, Lineage Cell Therapeutics, Janssen Research & Development, Belite Bio, Katairo, Cognition Therapeutics, Eye Co Pty Ltd, Applied Genetic Technologies Corporation (AGTC), Aviceda Therapeutics, Kodiak Sciences, Ascentage Pharma, OliX Pharmaceutical, Nanoscope Therapeutics, Inc., Biophytis, Eyestem, Eyevensys, SanBio, Beta Therapeutics, MacRegen, Amarna Therapeutics, MeiraGTx, Cognition Therapeutics, Ocugen, Catalyst Biosciences, Endogena Therapeutics, Oculogenex, Clover Therapeutics, Retrotope, Stuart Therapeutics, Surrozen, 4D Pharma, Ocular Therapeutix, and others.
• Key Dry Age-related Macular Degeneration pipeline therapies in various stages of development include ALK-001, Etamsylate, Zimura, Visomitin, Elamipretide, Risuteganib, GT005, GEM1003, RPESC-RPE-4W, MA09-hRPE, CPCB-RPE1, OpRegen, AAVCAGsCD59, Tinlarebant (LBS-008), Remofuscin, CT1812, Fludrocortisone acetate, Complement factor H, AVD-104, KSI-601, Alrizomadlin, OLX301A, MCO-030, BIO-201, Eyecyte-RPE, EYS809, SB 623, BT-2180, Mitia, AMA004, OCU410, IVT CB 2782-PEG, CTX010, CTX020, RT011, 4P-020,Research Programme: Dry Age-related Macular Degeneration (dAMD), Research programme: regenerative therapeutics, and others.
• The companies and academics are working to assess challenges and seek opportunities that could influence Dry Age-Related Macular Degeneration R&D. The therapies under development are focused on novel approaches to treat/improve Dry Age-Related Macular Degeneration.

Request a sample and discover more about the Dry Age-related Macular Degeneration Pipeline Outlook Report offerings @ https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Dry Age-related Macular Degeneration Overview
Age-related macular degeneration (AMD) is a degenerative disease of the center area of the ocular-posterior segment (the macula lutea) that causes slow degeneration in central vision and severe disability in affected persons. "Age-related" means that it mainly occurs with elderly adults, while "Macular" means that the macula part of the eye is damaged. AMD mostly affects people aged above 50, and it was first reported more than 80 years ago. Dry macular degeneration is a common eye disorder among people aged above 50 years. It causes blurred or reduced central vision due to thinning of the macula. The macula is the part of the retina responsible for clear vision in a direct line of sight. GA or choroidal neovascularization are two processes that produce photoreceptor failure in late AMD and can cause visual loss. Usually, dry AMD progresses very slowly whereas, some people experience severe visual impairment within days or weeks of the onset of wet AMD. The diagnostic methods of AMD include fundus imaging, fluorescein angiogenesis (FA), indocyanine green angiography (ICGA), optical coherence tomography (OCT), Optical coherence tomography angiography (OCTA), and artificial intelligence (AI). These techniques play an important role in the diagnosis of AMD and have their unique advantages. A detailed understanding of the molecular mechanisms underlying wet AMD has led to several robust FDA-approved therapies. In contrast, there are not any approved treatments for dry AMD. The management of dry AMD consists of observation, regular follow-up evaluations, and documentation for timely recognition of visual function deterioration with appropriate rehabilitation and early CNV detection.

Recent Breakthroughs of Dry Age-related Macular Degeneration Treatment Landscape
• In July 2021, IVERIC bio announced the early completion of patient enrollment in GATHER2, the Company's second pivotal clinical trial of Zimura® (avacincaptad pegol) in development for the treatment of Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD).
• In June 2021, Ocular Therapeutix and Mosaic Biosciences entered into strategic discovery collaboration targeting the treatment of dry age-related macular degeneration. Under the terms of the agreement, Ocular Therapeutix has agreed to fund the research performed under the collaboration and retains all program inventions and associated intellectual property.
• The US Food and Drug Administration (FDA) has granted Fast Track designation to Zimura (avacincaptad pegol), a novel complement C5 inhibitor, in development for the treatment of geographic atrophy secondary to dry age-related macular degeneration.
• In January 2021 Gemini Therapeutics announced that GEM103, the company's investigational treatment for dry AMD, had been granted Fast Track designation by the FDA.
• In September 2020, the US FDA had granted Fast Track designation to GT005 for the treatment of geographic atrophy secondary to dry age-related macular degeneration.
• In December 2020, Janssen Pharmaceuticals announced the acquisition of rights to Hemera Biosciences, LLC's investigational gene therapy HMR59, administered as a one-time, outpatient, intravitreal injection to help preserve vision in patients with geographic atrophy, a late-stage and severe form of age-related macular degeneration (AMD).
• On January 13, 2022, ONL Therapeutics, announced that it has closed on its second tranche of the Company's Series B financing. The total proceeds raised in the Series B was $46.9 million upon Achieving ONL1204 Development Milestones. The company is advancing ONL1204 into open-angle glaucoma and GA associated with dry AMD.

Find out more about the Dry Age-related Macular Degeneration Pipeline Disease @ https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Dry Age-related Macular Degeneration Emerging Drugs
• ALK-001: Alkeus Pharmaceuticals
• Zimura: Iveric bio
• Visomitin: Mitotech
• Risuteganib: Allegro Ophthalmics
• GT005: Gyroscope Therapeutics
• GEM103: Gemini Therapeutics

DelveInsight's Dry Age-related Macular Degeneration Pipeline report covers around 40+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Learn more about the Dry Age-related Macular Degeneration Pipeline Analysis @ https://www.delveinsight.com/report-store/dry-age-macular-degeneration-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Dry Age-related Macular Degeneration Pipeline Report
• Coverage- Global
• Dry Age-related Macular Degeneration Therapeutic Assessment By Dry Age-related Macular Degeneration Product Type
• Dry Age-related Macular Degeneration Therapeutic Assessment By Dry Age-related Macular Degeneration Clinical Stages
• Dry Age-related Macular Degeneration Therapeutics Assessment By Dry Age-related Macular Degeneration Therapeutics Route of Administration
• Dry Age-related Macular Degeneration Therapeutics Assessment By Dry Age-related Macular Degeneration Therapies Molecule Type
• Dry Age-related Macular Degeneration Therapeutics Assessment By Dry Age-related Macular Degeneration Therapies Mechanism of Action: Complement C5 inhibitors, Complement factor I replacements; Gene transference, Integrin inhibitors, Complement factor H replacements, Pluripotent stem cell therapies, Cell replacements, RNA interference, Gene transference; Vascular endothelial growth factor A inhibitors, Fibroblast growth factor inhibitor, Mitochondrial permeability transition pore inhibitors, Cardiolipin modulators.
• Key Dry Age-related Macular Degeneration Companies: Alkeus Pharmaceuticals, Dobecure, Iveric Bio, Mitotech, Stealth BioTherapeutics, Allergo Ophthalmics, Gyroscope Therapeutics, Gemini Therapeutics, Luxa Biotechnology, CHABiotech CO., Ltd, Regenerative Patch Technologies, Lineage Cell Therapeutics, Janssen Research & Development, Belite Bio, Katairo, Cognition Therapeutics, Eye Co Pty Ltd, Applied Genetic Technologies Corporation (AGTC), Aviceda Therapeutics, Kodiak Sciences, Ascentage Pharma, OliX Pharmaceutical, Nanoscope Therapeutics, Inc., Biophytis, Eyestem, Eyevensys, SanBio, Beta Therapeutics, MacRegen, Amarna Therapeutics, MeiraGTx, Cognition Therapeutics, Ocugen, Catalyst Biosciences, Endogena Therapeutics, Oculogenex, Clover Therapeutics, Retrotope, Stuart Therapeutics, Surrozen, 4D Pharma, Ocular Therapeutix and others
• Key Dry Age-related Macular Degeneration Pipeline Therapies: ALK-001, Etamsylate, Zimura, Visomitin, Elamipretide, Risuteganib, GT005, GEM1003, RPESC-RPE-4W, MA09-hRPE, CPCB-RPE1, OpRegen, AAVCAGsCD59, Tinlarebant (LBS-008), Remofuscin, CT1812, Fludrocortisone acetate, Complement factor H, AVD-104, KSI-601, Alrizomadlin, OLX301A, MCO-030, BIO-201, Eyecyte-RPE, EYS809, SB 623, BT-2180, Mitia, AMA004, OCU410, IVT CB 2782-PEG, CTX010, CTX020, RT011, 4P-020,Research Programme: Dry Age-related Macular Degeneration (dAMD), Research programme: regenerative therapeutics and others.

Table of Content
1. Introduction
2. Executive Summary
3. Dry Age-Related Macular Degeneration: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. ALK-001: Alkeus Pharmaceuticals
8. Mid Stage Products (Phase II)
9. Visomitin: Mitotech
10. Early stage products (Phase I/II)
11. RPESC-RPE-4W: Luxa Biotechnology
12. Inactive Products
13. Dry Age-Related Macular Degeneration Key Companies
14. Dry Age-Related Macular Degeneration Key Products
15. Dry Age-Related Macular Degeneration- Unmet Needs
16. Dry Age-Related Macular Degeneration- Market Drivers and Barriers
17. Dry Age-Related Macular Degeneration- Future Perspectives and Conclusion
18. Dry Age-Related Macular Degeneration Analyst Views
19. Dry Age-Related Macular Degeneration Key Companies
20. Appendix

Get a holistic view of the Dry Age-Related Macular Degeneration Drug Pipeline and Emerging Trends @ https://www.delveinsight.com/report-store/dry-age-macular-degeneration-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.